Page last updated: 2024-11-04

vorinostat and Body Weight

vorinostat has been researched along with Body Weight in 5 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively."1.34Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. ( Kerr, JS; Turner, KJ; Wise, LD, 2007)
" Four compounds having an MTD > or = 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model."1.32N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). ( Atadja, P; Bair, KW; Bontempo, J; Cesarz, D; Chandramouli, N; Chen, R; Cheung, M; Cornell-Kennon, S; Dean, K; Diamantidis, G; France, D; Green, MA; Howell, KL; Kashi, R; Kwon, P; Lassota, P; Martin, MS; Mou, Y; Perez, LB; Remiszewski, SW; Sambucetti, LC; Sharma, S; Smith, T; Sorensen, E; Taplin, F; Trogani, N; Versace, R; Walker, H; Weltchek-Engler, S; Wood, A; Wu, A, 2003)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Remiszewski, SW1
Sambucetti, LC1
Bair, KW1
Bontempo, J1
Cesarz, D1
Chandramouli, N1
Chen, R1
Cheung, M1
Cornell-Kennon, S1
Dean, K1
Diamantidis, G1
France, D1
Green, MA1
Howell, KL1
Kashi, R1
Kwon, P1
Lassota, P1
Martin, MS1
Mou, Y1
Perez, LB1
Sharma, S1
Smith, T1
Sorensen, E1
Taplin, F1
Trogani, N1
Versace, R1
Walker, H1
Weltchek-Engler, S1
Wood, A1
Wu, A1
Atadja, P1
McGee-Lawrence, ME1
McCleary-Wheeler, AL1
Secreto, FJ1
Razidlo, DF1
Zhang, M1
Stensgard, BA1
Li, X1
Stein, GS1
Lian, JB1
Westendorf, JJ1
Casto, BC1
Pereira, MA1
Wise, LD2
Turner, KJ1
Kerr, JS2
Spence, S1
Saldutti, LP1

Other Studies

5 other studies available for vorinostat and Body Weight

ArticleYear
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21

    Topics: Acetyltransferases; Acrylamides; Animals; Antineoplastic Agents; Body Weight; Cell Division; Dose-Re

2003
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
    Bone, 2011, May-01, Volume: 48, Issue:5

    Topics: Acetylation; Animals; Biomarkers; Body Weight; Bone Marrow Cells; Bone Remodeling; Bone Resorption;

2011
Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Body Weight; Budesonide; Chemop

2011
Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2007, Volume: 80, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Enzyme Inhibito

2007
Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2008, Volume: 83, Issue:1

    Topics: Administration, Oral; Animals; Body Weight; Dose-Response Relationship, Drug; Embryonic Development;

2008